The role of MRI as a surrogate outcome measure in multiple sclerosis

被引:84
作者
McFarland, HF [1 ]
Barkhof, F
Antel, J
Miller, DH
机构
[1] NINCDS, NIH, Neuroimmunol Branch, Bethesda, MD 20892 USA
[2] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, MD MR Ctr, Amsterdam, Netherlands
[3] Montreal Neurol Inst, Dept Neurol, Montreal, PQ, Canada
[4] NMR Res Unit, Inst Neurol, London, England
关键词
mri; outcome measure;
D O I
10.1191/1352458502ms767xx
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-con trolled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease, The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.
引用
收藏
页码:40 / 51
页数:12
相关论文
共 93 条
[61]   Surrogate markers in HIV disease [J].
Peto, T .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 :161-170
[62]   SURROGATE ENDPOINTS IN CLINICAL-TRIALS - DEFINITION AND OPERATIONAL CRITERIA [J].
PRENTICE, RL .
STATISTICS IN MEDICINE, 1989, 8 (04) :431-440
[63]   ESTIMATION OF METABOLITE CONCENTRATIONS FROM LOCALIZED IN-VIVO PROTON NMR-SPECTRA [J].
PROVENCHER, SW .
MAGNETIC RESONANCE IN MEDICINE, 1993, 30 (06) :672-679
[64]  
Rocca MA, 1999, AM J NEURORADIOL, V20, P821
[65]  
Rovaris M, 1999, AM J NEURORADIOL, V20, P813
[66]   Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS [J].
Rudick, RA ;
Fisher, E ;
Lee, JC ;
Simon, J ;
Jacobs, L .
NEUROLOGY, 1999, 53 (08) :1698-1704
[67]   Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination [J].
Sailer, M ;
O'Riordan, JI ;
Thompson, AJ ;
Kingsley, DP ;
MacManus, DG ;
McDonald, WI ;
Miller, DH .
NEUROLOGY, 1999, 52 (03) :599-606
[68]   Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients [J].
Sarchielli, P ;
Presciutti, O ;
Pelliccioli, GP ;
Tarducci, R ;
Gobbi, G ;
Chiarini, P ;
Alberti, A ;
Vicinanza, E ;
Gallai, V .
BRAIN, 1999, 122 :513-521
[69]   IMMUNOCYTOCHEMICAL LOCALIZATION OF N-ACETYL-ASPARTATE WITH MONOCLONAL-ANTIBODIES [J].
SIMMONS, ML ;
FRONDOZA, CG ;
COYLE, JT .
NEUROSCIENCE, 1991, 45 (01) :37-45
[70]   Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis [J].
Simon, JH ;
Jacobs, LD ;
Campion, M ;
Wende, K ;
Simonian, N ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Alam, JJ ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Lajaunie, M ;
Martens-Davidson, AL ;
Meyer, MJ ;
Sheeder, J ;
Choi, K ;
Scherzinger, AL ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
Weinstock-Guttman, B ;
Whitham, RH .
ANNALS OF NEUROLOGY, 1998, 43 (01) :79-87